Korro Bio, Inc. (KRRO)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on KRRO

With Tiblio's Option Bot, you can configure your own wheel strategy including KRRO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol KRRO
  • Rev/Share 0.5137
  • Book/Share 14.8074
  • PB 0.9941
  • Debt/Equity 0.3252
  • CurrentRatio 9.4119
  • ROIC -0.4989

 

  • MktCap 138228013.0
  • FreeCF/Share -7.9969
  • PFCF -1.8419
  • PE -1.5803
  • Debt/Assets 0.2235
  • DivYield 0
  • ROE -0.5164

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation KRRO Cantor Fitzgerald -- Overweight -- $74 April 29, 2025
Initiation KRRO Chardan Capital Markets -- Buy -- $25 April 16, 2025
Initiation KRRO Oppenheimer -- Outperform -- $155 Jan. 10, 2025
Initiation KRRO Raymond James -- Strong Buy -- $153 Oct. 21, 2024

News

Korro to Present at the TD Cowen 45th Annual Health Care Conference
KRRO
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. ET at the Boston Marriott Copley Place. Todd Chappell, Chief Operating Officer, will also participate in 1x1 investor meetings at the conference.

Read More
image for news Korro to Present at the TD Cowen 45th Annual Health Care Conference

About Korro Bio, Inc. (KRRO)

  • IPO Date 2019-10-03
  • Website https://www.korrobio.com
  • Industry Biotechnology
  • CEO Ram Aiyar MBA,
  • Employees 112
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.